Clinical Trial: A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome

Brief Summary:

The objectives of the study are:

  1. Evaluation of the safety profile of imatinib mesylate in patients with idiopathic hypereosinophilic syndrome resistant or refractory to, or intolerant of, prednisone, hydroxyurea or interferon-alpha, or untreated patients carrying the Fip1L1-PDGFRA fusion protein.
  2. Evaluation of the efficacy of imatinib mesylate in patients with idiopathic hypereosinophilic syndrome
  3. Analysis of patient's blood samples for the detection of activated kinases.

Detailed Summary:
Sponsor: Novartis Pharmaceuticals

Current Primary Outcome: Rate of complete and partial response and relapse

Original Primary Outcome:

Current Secondary Outcome:

  • Bone Marrow Analysis
  • Peripheral blood detection of Fip1L1-PDGFRA tyrosine kinase
  • Disease-Related Symptoms and Signs
  • Organ Involvement


Original Secondary Outcome:

Information By: Novartis

Dates:
Date Received: September 13, 2005
Date Started: September 2002
Date Completion:
Last Updated: April 29, 2012
Last Verified: April 2012